{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positive+Choices", "query": { "intervention": "Positive Choices" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 201, "total_pages": 21, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positive+Choices&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-13T04:50:39.814Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04082364", "title": "Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Gastric Cancer", "Gastroesophageal Junction Cancer", "HER2-positive Gastric Cancer" ], "interventions": [ { "name": "margetuximab", "type": "BIOLOGICAL" }, { "name": "Retifanlimab", "type": "BIOLOGICAL" }, { "name": "Tebotelimab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Chemotherapy", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2019-09-30", "completion_date": "2025-03-25", "has_results": true, "last_update_posted_date": "2025-06-08", "last_synced_at": "2026-09-13T04:50:39.814Z", "location_count": 28, "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 25 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Salinas", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04082364" }, { "nct_id": "NCT02603133", "title": "Web-based Implementation for the Science of Enhancing Resilience Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Burnout, Professional", "Resilience, Psychological" ], "interventions": [ { "name": "Three Good Things", "type": "BEHAVIORAL" }, { "name": "Gratitude", "type": "BEHAVIORAL" }, { "name": "Random Acts of Kindess", "type": "BEHAVIORAL" }, { "name": "Awe", "type": "BEHAVIORAL" }, { "name": "1 Good Chat", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 2650, "start_date": "2016-07", "completion_date": "2019-07", "has_results": false, "last_update_posted_date": "2023-02-10", "last_synced_at": "2026-09-13T04:50:39.814Z", "location_count": 9, "location_summary": "Palo Alto, California • Stanford, California • Boston, Massachusetts + 5 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02603133" }, { "nct_id": "NCT05840211", "title": "Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced or Unresectable Metastatic Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "Sacituzumab Govitecan-hziy", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 654, "start_date": "2023-05-08", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2025-10-03", "last_synced_at": "2026-09-13T04:50:39.814Z", "location_count": 30, "location_summary": "Chandler, Arizona • Los Angeles, California • Palo Alto, California + 25 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Littleton", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05840211" }, { "nct_id": "NCT03906227", "title": "Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "ANCA Associated Vasculitis" ], "interventions": [ { "name": "ENUMERATION OF CD5+ B Cells", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 9, "start_date": "2019-06-28", "completion_date": "2025-02-27", "has_results": true, "last_update_posted_date": "2025-11-26", "last_synced_at": "2026-09-13T04:50:39.814Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03906227" }, { "nct_id": "NCT00681200", "title": "Evaluating Mechanisms of Blood Pressure Reduction Using Meditation in Hypertensive African Americans", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Enhanced health education", "type": "BEHAVIORAL" }, { "name": "Transcendental Meditation program", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Maharishi International University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 152, "start_date": "2008-04", "completion_date": "2012-05", "has_results": false, "last_update_posted_date": "2022-04-14", "last_synced_at": "2026-09-13T04:50:39.814Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00681200" }, { "nct_id": "NCT04162847", "title": "Harnessing Mobile Technology to Reduce Mental Health Disorders in College Populations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anxiety Disorders", "Depressive Disorder", "Eating Disorders" ], "interventions": [ { "name": "SilverCloud Health Intervention", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6205, "start_date": "2019-10-07", "completion_date": "2023-12-31", "has_results": true, "last_update_posted_date": "2025-04-23", "last_synced_at": "2026-09-13T04:50:39.814Z", "location_count": 4, "location_summary": "Palo Alto, California • Ann Arbor, Michigan • St Louis, Missouri + 1 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "State College", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04162847" }, { "nct_id": "NCT06942442", "title": "A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HLA-A*0201 Positive Cells Present", "Clear Cell Sarcoma (CCS)" ], "interventions": [ { "name": "Physician's Choice", "type": "DRUG" }, { "name": "Tebentafusp", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sarcoma Alliance for Research through Collaboration", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2025-10-22", "completion_date": "2030-10-01", "has_results": false, "last_update_posted_date": "2025-12-26", "last_synced_at": "2026-09-13T04:50:39.814Z", "location_count": 2, "location_summary": "Los Angeles, California • New York, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06942442" }, { "nct_id": "NCT06886971", "title": "Strategies to AchieVe Viral Suppression for Youth With HIV", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Human Immunodeficiency Virus (HIV) Infection" ], "interventions": [ { "name": "The SAVVY intervention includes CHOICE counseling and shared decision-making regarding ART preference (informed by the evidence-based HIV-ASSIST) and facilitating LA-ART access", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "12 Years to 30 Years" }, "enrollment_count": 288, "start_date": "2024-11-10", "completion_date": "2028-07-31", "has_results": false, "last_update_posted_date": "2026-02-04", "last_synced_at": "2026-09-13T04:50:39.814Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06886971" }, { "nct_id": "NCT03047590", "title": "Comparison of Affect-based, Self-selected, and Traditional Exercise Prescriptions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Physical Activity" ], "interventions": [ { "name": "Choice-based Exercise Intensity", "type": "BEHAVIORAL" }, { "name": "Positive Affect Focus", "type": "BEHAVIORAL" }, { "name": "Heart rate-based Exercise Intensity", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 159, "start_date": "2017-02-21", "completion_date": "2018-03-29", "has_results": false, "last_update_posted_date": "2018-07-09", "last_synced_at": "2026-09-13T04:50:39.814Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03047590" }, { "nct_id": "NCT04975308", "title": "A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms", "Neoplasm Metastasis" ], "interventions": [ { "name": "Imlunestrant", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 874, "start_date": "2021-10-04", "completion_date": "2027-08", "has_results": true, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-09-13T04:50:39.814Z", "location_count": 48, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Greenbrae, California + 29 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04975308" } ] }